The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://rafaelfval757059.blogcudinti.com/39197015/glp-3-retatrutide-a-comparative-analysis